Literature DB >> 30904948

Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4).

Mirjam Renovanz1,2, Sari Soebianto3, Helena Tsakmaklis3, Naureen Keric3, Minou Nadji-Ohl4, Manfred Beutel5, Florian Ringel3, Daniel Wollschläger6, Anne-Katrin Hickmann4,7.   

Abstract

PURPOSE: Depressive symptoms of patients with intracranial tumors need to be assessed adequately. The Patient Health Questionnaire for Depression and Anxiety (PHQ-4) is an ultra-short screening tool consisting of four items, a cutoff of six indicates depressive symptoms. The aim was to assess patients' psychological burden by the PHQ-4 compared with the results of well-established screening instruments.
METHODS: Patients were screened three times after primary diagnosis postoperatively (t1), after 3 (t2) and 6 (t3) months using the PHQ-4, the Hornheide Screening Instrument (HSI), the NCCN Distress Thermometer (DT), and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire with its brain module (EORTC QLQ-C30 + BN20). Demographic, tumor-related data, and Karnofsky Performance Scale (KPS) were analyzed. A cutoff value for PHQ-4 indicating a need for support or increased distress was determined by applying receiver operating characteristic (ROC).
RESULTS: The proportion of patients reaching a total score ≥ 6 was n = 32 out of 139 (23%) at t1; at t2, n = 12 out of 117 (10%) scored ≥ 6. At t3, n = 8 out of 96 (8%) scored ≥ 6. At t1, PHQ-4 scores did not differ significantly between gender, age groups, and tumor laterality. A cutoff value of 2.5 was identified to moderately discriminate between patients in or not in distress (sensitivity 76.8%) and between patients wishing further, specific support or not (sensitivity 82.5%).
CONCLUSION: The PHQ4 can be applied in this patient cohort to detect those with relevant psychological comorbidities. The cutoff value should be re-evaluated in a larger cohort as we observed that a cutoff of 6, as recommended previously, may be too high in order to detect affected patients adequately.

Entities:  

Keywords:  Brain tumor; Cancer; Distress; Intracranial tumor; Oncology; Psychosocial burden; Quality of life; Screening

Mesh:

Year:  2019        PMID: 30904948     DOI: 10.1007/s00520-019-04718-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  38 in total

1.  Psychological distress symptoms' clusters in brain tumor patients: factor analysis of depression and anxiety scales.

Authors:  Adomas Bunevicius; Sarunas Tamasauskas; Vytenis Deltuva; Arimantas Tamasauskas; Robertas Bunevicius
Journal:  Psychooncology       Date:  2013-08-03       Impact factor: 3.894

2.  Understanding recruitment and retention in neurological research.

Authors:  Alyssa Newberry; Paula Sherwood; Allison Hricik; Sarah Bradley; Jean Kuo; Elizabeth Crago; Leslie A Hoffman; Barbara A Given
Journal:  J Neurosci Nurs       Date:  2010-02       Impact factor: 1.230

3.  Distress in patients with newly diagnosed brain tumours.

Authors:  S Goebel; A M Stark; L Kaup; M von Harscher; H M Mehdorn
Journal:  Psychooncology       Date:  2011-03-30       Impact factor: 3.894

4.  An ultra-brief screening scale for anxiety and depression: the PHQ-4.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Bernd Löwe
Journal:  Psychosomatics       Date:  2009 Nov-Dec       Impact factor: 2.386

5.  Assessing psychological and supportive care needs in glioma patients - feasibility study on the use of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the Supportive Care Needs Survey Screening Tool (SCNS-ST9) in clinical practice.

Authors:  M Renovanz; A-K Hickmann; J Coburger; K Kohlmann; M Janko; A-K Reuter; N Keric; M Nadji-Ohl; J König; S Singer; A Giese; M Hechtner
Journal:  Eur J Cancer Care (Engl)       Date:  2016-10-24       Impact factor: 2.520

Review 6.  Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis.

Authors:  Alex J Mitchell
Journal:  J Natl Compr Canc Netw       Date:  2010-04       Impact factor: 11.908

7.  How to identify patients in need of psychological intervention.

Authors:  Gerhard Strittmatter; Marlene Tilkorn; Reinhard Mawick
Journal:  Recent Results Cancer Res       Date:  2002

8.  Screening for distress and depression in cancer patients: is ultrashort depression screening a valid measure in the UK? A prospective validation study.

Authors:  Joseph Low; Sue Gessler; Rachael Williams; Emma Daniells; Veronica Brough; Adrian Tookman; Louise Jones
Journal:  J Pain Symptom Manage       Date:  2009-04-02       Impact factor: 3.612

9.  Screening for distress in patients with intracranial tumors during the first 6 months after diagnosis using self-reporting instruments and an expert rating scale (the basic documentation for psycho-oncology short form - PO-Bado SF).

Authors:  Mirjam Renovanz; Helena Tsakmaklis; Sari Soebianto; Isabell Neppel; Minou Nadji-Ohl; Manfred Beutel; Andreas Werner; Florian Ringel; Anne-Katrin Hickmann
Journal:  Oncotarget       Date:  2018-07-24

10.  Modelling attrition and nonparticipation in a longitudinal study of prostate cancer.

Authors:  Samantha Spiers; Evrim Oral; Elizabeth T H Fontham; Edward S Peters; James L Mohler; Jeannette T Bensen; Christine S Brennan
Journal:  BMC Med Res Methodol       Date:  2018-06-20       Impact factor: 4.615

View more
  5 in total

1.  Effects and Implementation of a Mindfulness and Relaxation App for Patients With Cancer: Mixed Methods Feasibility Study.

Authors:  Michael Mikolasek; Claudia Margitta Witt; Jürgen Barth
Journal:  JMIR Cancer       Date:  2021-01-13

2.  The factor structure and measurement invariance of the PHQ-4 and the prevalence of depression and anxiety in a Southeast Asian context amid the COVID-19 pandemic.

Authors:  Norman B Mendoza; Cherry E Frondozo; John Ian Wilzon T Dizon; Jet U Buenconsejo
Journal:  Curr Psychol       Date:  2022-03-01

3.  Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial.

Authors:  Petra Huehnchen; Nikola Bangemann; Sandra Lischewski; Stefanie Märschenz; Friedemann Paul; Tanja Schmitz-Hübsch; Jens-Uwe Blohmer; Cornelia Eberhardt; Geraldine Rauch; Agnes Flöel; Sophie Adam; Philipp Schwenkenbecher; Ivo Meinhold-Heerlein; Oliver Hoffmann; Tjalf Ziemssen; Matthias Endres; Wolfgang Boehmerle
Journal:  Front Med (Lausanne)       Date:  2022-08-11

4.  Hope and Distress Are Not Associated With the Brain Tumor Stage.

Authors:  Simone Mayer; Stefanie Fuchs; Madeleine Fink; Norbert Schäffeler; Stephan Zipfel; Franziska Geiser; Heinz Reichmann; Björn Falkenburger; Marco Skardelly; Martin Teufel
Journal:  Front Psychol       Date:  2021-05-28

5.  The methamphetamine epidemic among persons who inject heroin in Hai Phong, Vietnam.

Authors:  Don C Des Jarlais; Jonathan Feelemyer; Kamyar Arasteh; Duong Thi Huong; Khuat Thi Hai Oanh; Pham Minh Khue; Hoang Thi Giang; Nham Thi Tuyet Thanh; Jean Pierre Moles; Vu Hai Vinh; Roselyne Vallo; Catherine Quillet; Delphine Rapoud; Laurent Michel; Didier Laureillard; Nicolas Nagot
Journal:  J Subst Abuse Treat       Date:  2021-02-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.